you, DA. Thank
of Eledon's expansion, responses pathway class lead off Physiologically, start target of expansion to anti-CDXX plays that story, switching immune you I'll Fc amplify overview been of response. cells, effector antibody pro-inflammatory antibody pivotal engagement an and a CDXX for has giving brief AT-XXXX, immune the that production secretion as lymphocytes. function, in are antibody cells as results these B of the and asset production and those of mediating an The CDXX cytokines of For CDXX-CDXX development locking the ligand ligand in new role both our interaction the polarization of of IgGX function. a by clonal ligand decades, because cell immune modulation germinal well activation by an drug receptors clonal and through in cellular attractive system the antibody pro-inflammatory T
by as as the binds signaling such CDXX presenting costimulatory receptors, a simultaneously ligand under on to peptides antigen-presenting initiation are receptors immune mitigated is cell MHC lymphocytes. receptor antigen-presenting on CDXX The when costimulatory cells robust foreign of T cells, these response
may We preclinical of long-term CDXX are in been anti-CDXX be an ligand targeting the the to efficacious efficacy more acute ligand ligand focusing of than as the transplant the our targeting be and since receptor, biological efforts preclinical rejection. targeting models shown benefit receptor. the rather has in antagonist prevention on X antibody targeting by showed the mechanisms development for well as autoimmunity There over and allograft of the
is antigen-presenting whereas on cells all in cells tissues. and macrophages, activated differences more specialized and restricted the the cells, cells dendritic is first is receptor The in ligand on presenting including present monocytes, broadly antigen distribution, since more expression and its endothelial present cellular lymphocytes, platelets,
blocking cytotoxic the as thus the ligand cells, receptor the switching other cells; inhibiting cells and however, CDX CDXX class blocking of Second positive of B-cell polarization inhibits well. receptors, well targeting pro-inflammatory including inhibits polarization CDX-positive antigen CDXX that both and pro-inflammatory the is activation ligand on also as integral as receptors presenting T T
ligand allograft well as and lymphocytes FoxPX-positive environment CDX-positive third, as become Tregs, tolerogenic autoimmunity. polarizes to finally, potentially rejection blocking context also thus a transplant creating And of more the in the preventing
advance II clinical based to rejection allograft the rejection, preclinical at anti-CDXX is reduction historical transfer indications to antibodies. data allograft kidney cell We can has cell be allograft with to CDXX the trials, AT-XXXX that efficacious Preclinical plan been autoimmune receptor. models blocking animal islet We prevention of some molecule and CDXX nephritis prevention and CDXX selected acute that was induce in X ligand or these of data ligand to tolerance. way islet most to disease rejection, on our up suggest transplant ALS. transplant, renal Phase either Blocking generated ligand long-term and and shown compared cases, blocking in transplant prevent long-term in preventing more effective in the
Importantly, is lymphopenia. systemic not ligand associated targeting CDXX with
of beta pancreas. or with is preventing The the ability exposure This potential toxicity to prevent clinical the management and insulin has potentially to nephrotoxicity, in to opportunities acute CNIs. associated the associated rejection, diabetes. to cells due transplantation diabetes calcineurin with Chronic infections mitigating organ in chronic is calcineurin of increased transplant and transform of cardiotoxicity, in CNIs the on inhibitors thus to in inhibitors rejection increase the producing type the graft CNIs in an absence X induction
CNI and transplants exposing islet been in days transplant cells part multiple yet to islet toxic thus requirement the after cell rejection a eliminate CNIs to up to with order is cell mass therefore may Similarly, acute transplant transplanted insulin. risk a to cell as exogenous transplantation, cells for transplantation and cell the the for of transplanted obtain islet CNIs die the and rejection, option by the required to islet due toxicity Adoption to in of and to islet of toxicity cell loss within are in that cure hampered are requiring subjects islet result sufficient cell part islet XX% potential functional brittle dysfunction. diabetes prevent associated treatment in
potential for that become CNIs islet cure believe with result, with potentially for a even diabetes. outcomes functional X cell living as transplant, We clinical option and to improve thus cell AT-XXXX transplants allowing islet cell and may persons a treatment with viable islet a survival associated type replacing
of data In clinical autoimmunity, of ameliorates a of preclinical CDXX signaling biomarkers ligand history on nephritis, the autoimmune There are blocking focusing modifies which diseases are that and progression, kidney. long demonstrating disease diseases we is Moreover, soluble disease example. as nephropathy, focal renal disease CDXX correlates glomerulosclerosis such and segmental these. function in flares as or for ligand diseases with and IgA such improves often autoimmune nephritis FSGS, lupus autoimmune in
improves model development ALS is has program clinical of ALS preclinical in on ALS ALS TDI, also survival XXX soluble with progression Institute, Therapy can the improves flares diseases, one models of is ALS function in according drugs slows TDI of rodent function. or ALS. that down a progression, at Development rodent with handful correlate conducted Similarly, only in And CDXX compounds CDXX screened ALS. a ALS positive ligand CDXX disease Two in approximately soluble TDI. muscle of ligand data to ligand can correlate blocking autoimmune disease based how and in
study tolerability. our X humans. October safety XXXX. in people initiated II a study AT-XXXX. endpoint study escalating in of is and Shifting ALS doses biomarker Eledon ascending and This of is open-label a of of the Phase dose is of with first AT-XXXX to primary trial with safety the Thus, in study trials. living clinical The XX-week the multiple dose AT-XXXX
and pro-inflammatory circulation, disease We and IL-X such neurofilament of chain including will and signaling TNF surrogate engagement, as progression. also levels assess endpoints, multiple a as exploratory health neuronal alpha biomarker marker target and light
related in as respiratory ALS expected top some peaks from as Finally, change track, XX-week and first data scale, looking in we'll recent exploratory at on significantly in clinical be anticipate rating such although these disease in functional changes to the as progression we efficacy the study. trial are in reporting half not or well Despite trial of this ALSFRS to XXXX. on be function, to endpoints enrollment continues this COVID-XX, line the
Canada proceed initiation single-arm and X is In study received reduction people trial and in clinical glucose diabetes. clearance with the type we with This AT-XXXX type safety transplantation for last HbaXc, insulin II of and cell primary year, November Phase islet X independence, of control from with a survival Health graft in endpoints open-label tolerability, a to of assessing diabetes.
be will assessing awareness function. events renal well We as also hypoglycemic as
before on early site stopped basis and study because in of transplants of XXXX previously, Canada COVID-related our data in performing in cell anticipate that that announced interim first COVID-XX, learned we transplant patient we this of first we quarter our Despite in able January reinitiating February in generate to now half these be planned second transplants temporary still we'll in As islet XXXX. of performing we cell a the to delay, expect as enroll and the XXXX. islet voluntarily
quarter second from regulatory of clinical the II we including renal pending XXXX. to trial target the clearance, end transplantation, at In the Phase the FDA, initiate terms of
after Finally, indication discuss renal transplantation our we'll study. specific fourth initiated we the
study With from to characterization and data, Phase having look we the Conference in studies of in to regards AT-XXXX well data, present releasing American non-human we the prevention to preclinical of I primate cell June, in data transplant clinical forward and of islet Transplant including assays presentations posters rejection. plan AT-XXXX in-vitro where as the of AT-XXXX as at
Let me Officer, now Paul Chief Little. turn the over to our Financial call
